Group 1 - The company Aikolan (SZ 300816) announced the resignation of non-independent director Jiang Renjian due to personal reasons, while he will continue to serve as CFO and board secretary [1] - Aikolan's revenue composition for the year 2024 is reported to be 97.51% from engine exhaust after-treatment and 2.49% from other businesses [1] - As of the latest report, Aikolan's market capitalization stands at 3.1 billion yuan [2]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：请总经理对公司AI与医疗数字化进行分析？ 艾可蓝（300816.SZ）9月11日在投资者互动平台表示，目前，公司主营业务仍是发动机尾气后处理产品 及大气环保相关产品的研发、生产和销售。近年来，公司积极探索多元化发展，围绕绿色与智慧两大主 题，在优势细分领域及垂直应用上展开产业布局。其中，智慧业务方面，公司正积极布局AI与医疗数 字化领域，提供从数据洞察到AI Agent落地的一站式解决方案，通过聚焦AI Agent技术在医疗场景的创 新应用，推动行业智能化升级，并助力医疗企业实现数字化转型。目前，公司的AI医疗业务尚处起步 阶段，对公司业绩不会造成重大影响，请投资者理性投资，注意风险。 ...

每经AI快讯，艾可蓝（SZ 300816，收盘价：38.45元）8月28日晚间发布公告称，公司第四届第七次董 事会会议于2025年8月28日以现场表决与通讯表决相结合的方式召开。会议审议了《关于修订 <董事会 秘书工作细则> 的议案》等文件。 2024年1至12月份，艾可蓝的营业收入构成为：发动机尾气后处理占比97.51%，其他业务占比2.49%。 截至发稿，艾可蓝市值为31亿元。 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ （记者 王晓波） ...

Group 1 - Yinlun Co., Ltd. plans to establish a joint venture company, Suzhou Yizhi Lingqiao Drive Technology Co., Ltd., with an investment of 10 million yuan, holding a 20% stake, to enhance the development of embodied intelligent robot components [1] - Zhimin Da's controlling shareholder plans to transfer 5.03 million shares, representing 3.00% of the total share capital, through an inquiry transfer method [1][2] - ST Ningke's subsidiary plans to invest 100 million yuan in a technical transformation project for the production of bio-fermentation products, aiming to enhance market competitiveness [3][4] Group 2 - Fujian Jinsen's chairman resigned due to work reasons, and the resignation will take effect after the election of a new chairman [5][6] - Kanghong Pharmaceutical's subsidiary received approval for clinical trials of Songling Xue Mai Kang capsules, aimed at treating functional ventricular premature beats [7][8] - Ruizhi Pharmaceutical plans to sell a 32.59% stake in its associate company, Guangdong Shenghetang Health Food Co., Ltd., for 60 million yuan [9] Group 3 - Meili Cloud's shareholder, China Metallurgical Paper Group, is undergoing bankruptcy reorganization, with its shares frozen and partially pledged [10] - Mongolian Grass Ecological plans to raise up to 1.495 billion yuan through a private placement for various ecological projects and working capital [11] - Aikelan's major shareholder plans to reduce their stake by up to 3% due to personal funding needs [12] Group 4 - Chaojie Co., Ltd. has three shareholders planning to reduce their stakes by a total of up to 3.73% for personal funding needs [13] - Haitai Biological's director plans to reduce their stake by up to 0.14% for personal funding needs [14] - New Guodu's executives plan to reduce their stakes by a total of up to 50.19 million shares for personal funding needs [15] Group 5 - Zhiguang Electric's vice chairman plans to reduce their stake by up to 304.06 million shares for personal funding needs [16] - *ST Jinbi's controlling shareholder plans to transfer 47.0853 million shares, making Yuan Yi Cheng Wu the new controlling shareholder [17][18] - Kaizhong Precision received a project designation from a leading global new energy battery manufacturer, with expected sales of approximately 700 million yuan [19][20] Group 6 - Defang Nano's director plans to reduce their stake by up to 133,200 shares for personal funding needs [21] - ST Hongtai's stock will have its risk warning removed, changing its name and increasing the price fluctuation limit [22] - Guoanda's directors plan to reduce their stakes by a total of up to 101,700 shares for personal funding needs [23] Group 7 - Lanshi Heavy Industry plans to acquire 100% of Qingdao Equipment for 99.9821 million yuan to enhance its delivery capabilities [24] - Qingdao Bank's major shareholder plans to increase its stake to no more than 19.99%, pending regulatory approval [25]

艾可蓝于2020年2月10日登陆深交所创业板，首次公开发行2000.00万股，发行价格为20.28元/股， 保荐机构为东兴证券，保荐代表人为崔永新、覃新林。 艾可蓝此次募集资金总额为4.06亿元，扣除发行费用后募集资金净额为3.65亿元，拟投资于以下项 目：发动机尾气后处理产品升级扩产项目、研发中心建设项目、补充流动资金。 艾可蓝此次发行费用为4042.08万元，其中，东兴证券获得承销费用和保荐费用2830.19万元。 艾可蓝实控人为刘屹，中国国籍，拥有美国永久居留权。刘屹持有艾可蓝31,108,572股，持股比例 为38.89%，其中已质押7,900,000股，占其所持股份比例的25.39%，占公司总股本比例的9.88%。 艾可蓝2024年年报显示，ZHUQING(朱庆)系公司董事、子公司总经理，任职状态为离任，任期起 始日期为2015年11月8日，任期终止日期为2024年11月22日。 据艾可蓝2023年年报披露，ZHU QING(朱庆)，男，加拿大籍，拥有中国永久居留权，1964年5月 生，研究生学历。1985年9月至1990年8月，任北京北方特种车辆研究所助理工程师；1990年8月至1993 年3月， ...

5月12日晚间，艾可蓝（300816）公告，公司于近日收到控股股东、实际控制人刘屹的通知，获悉其与 广东南传私募基金管理有限公司(代表"南传烽火3号私募证券投资基金")(以下简称"南传私募")就终止协 议转让公司部分股份事宜达成一致意见，并签署了《股份转让终止协议》。 回溯前情，去年12月12日，刘屹与南传私募签署了《刘屹与广东南传私募基金管理有限公司(代表"南传 烽火3号私募证券投资基金")之股份转让协议》，并于12月20日签署了《股份转让协议之补充协议》， 刘屹拟通过协议转让的方式将其持有的公司400万股无限售流通股(占公司总股本的5.00%，占剔除回购 专用证券账户中股份数量后公司总股本的5.08%)转让给南传私募。 最新公告显示，目前，刘屹与南传私募尚未办理完成相关股份转让手续，因客观条件变化，双方在自愿 平等的基础上友好协商，决定终止本次股份协议转让事项，双方互不承担违约责任。刘屹与南传私募签 署了《股份转让终止协议》。 截至目前，刘屹持有艾可蓝3110.86万股股份，占公司总股本的38.89%(占剔除回购专用证券账户中股份 数量后公司总股本的39.51%)。艾可蓝表示，本次协议转让终止不会导致公司 ...

Group 1 - Aikolan's controlling shareholder Liu Yi terminated the share transfer agreement for 4 million shares, which represents 5% of the company's total share capital, with no change in control [1] - Wancheng Group announced a cash dividend of 4.00 yuan per 10 shares, totaling 71.9959 million yuan, with the record date on May 19, 2025 [1] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation, acquiring a total of 7% equity in the company [2] Group 2 - China Resources Double Crane's subsidiaries received approval for two drugs, indicating progress in their product pipeline [3] - Fosun Pharma's subsidiary's drug was included in the breakthrough therapy program, highlighting its innovative potential [4] - Zhongheng Group's subsidiary received approval for naloxone injection, enhancing its product offerings [5] Group 3 - Shenzhen Airport reported a passenger throughput of 5.3202 million in April, a year-on-year increase of 23.50% [8] - Hangzhou Bank successfully issued 5 billion yuan in technology innovation bonds, aimed at supporting tech innovation [10] - Jiuzhou Pharmaceutical received approval for a raw material drug used in treating severe depression, expanding its product range [12] Group 4 - Aihua Group reported a 25.38% decline in revenue for the first four months of the year, indicating potential challenges [27] - Changhua Group received a project designation notice from a well-known new energy vehicle company, with an expected total sales amount of approximately 108 million yuan [28] - Nanchao Food reported a slight revenue decrease of 0.98% in April, reflecting market conditions [30]